GSK PLC-SPON ADR (GSK) Forecast, Price Target & Analyst Ratings

NYSE:GSK • US37733W2044

Current stock price

58.21 USD
-0.15 (-0.26%)
At close:
58.26 USD
+0.05 (+0.09%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GSK PLC-SPON ADR (GSK).

Forecast Snapshot

Consensus Price Target

Price Target
$56.15
-3.55% Downside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Apr 29, 2026
Period
Q1 / 2026
EPS Estimate
£0.92
Revenue Estimate
7.916B
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
68.75%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$56.15
Upside
-3.55%
From current price of $58.21 to mean target of $56.15, Based on 32 analyst forecasts
Low
$39.63
Median
$53.23
High
$77.87

Price Target Revisions

1 Month
0.00%
3 Months
10.45%

Price Target Summary

32 Wall Street analysts provided a forecast for the next 12 months for GSK. The average price target is 56.15 USD. This implies a price decrease of -3.55% is expected in the next year compared to the current price of 58.21.
The average price target has been revised upward by 10.45% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

GSK Current Analyst RatingGSK Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 5 10

Analyst Ratings History

GSK Historical Analyst RatingsGSK Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 10 20 30

Analyst Ratings Consensus

ChartMill Buy Consensus
68.75%
GSK was analyzed by 32 analysts. The buy percentage consensus is at 69. So analysts seem to be have mildly positive about GSK.
In the previous month the buy percentage consensus was at a similar level.
GSK was analyzed by 32 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-01-06BarclaysDowngrade Equal-Weight -> Underweight
2024-11-12JefferiesDowngrade Buy -> Hold
2024-10-31GuggenheimDowngrade Buy -> Neutral
2024-07-08UBSDowngrade Buy -> Neutral
2024-07-02JefferiesMaintains Buy -> Buy
2024-05-30Goldman SachsInitiate Neutral
2024-03-04GuggenheimUpgrade Neutral -> Buy
2024-01-23Morgan StanleyInitiate Equal-Weight
2024-01-03JefferiesUpgrade Hold -> Buy
2022-02-11DZ BankDowngrade Buy -> Hold
2021-11-05BarclaysUpgrade Underweight -> Equal-Weight
2021-07-29BarclaysReiterate Underweight
2021-07-08Berenberg BankReiterate Buy
2021-07-07Liberum CapitalReiterate Reiteration
2021-06-24Deutsche BankUpgrade Hold
2021-06-22Shore CapitalReiterate Hold
2021-06-16Libertas PartnersReiterate Buy
2021-06-14Berenberg BankReiterate Buy
2021-06-11Deutsche BankReiterate Sell
2021-05-19Deutsche BankReiterate Sell
2021-05-10Berenberg BankReiterate Buy
2021-04-21Shore CapitalReiterate Hold
2021-04-16Berenberg BankReiterate Buy
2021-04-15Liberum CapitalReiterate Buy
2021-04-15CitigroupReiterate Neutral

Next Earnings Forecast Details

Next Earnings Details

Release Date
Apr 29, 2026
Period
Q1 / 2026
EPS Estimate
£0.92
Revenue Estimate
7.916B
Revenue Q2Q
5.32%
EPS Q2Q
0.81%
Number of Analysts
9

Next Earnings Revisions

Revenue (1 Month)
0.14%
Revenue (3 Months)
-1.56%
EPS (1 Month)
0.87%
EPS (3 Months)
-6.63%

Next Earnings Summary

GSK is expected to report earnings on 4/29/2026. The consensus EPS estimate for the next earnings is 0.92 USD and the consensus revenue estimate is 7.92B USD.
The next earnings revenue estimate has been revised downward by 1.56% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
GSK revenue by date.GSK revenue by date.
30.328B
3.42%		31.376B
3.46%		32.667B
4.11%		34.856B
6.70%		36.328B
4.22%		37.38B
2.90%		38.855B
3.95%		38.569B
-0.74%		38.852B
0.73%		37.118B
-4.46%		36.711B
-1.10%
EBITDA
YoY % growth
GSK ebitda by date.GSK ebitda by date.
10.615B
0.69%		10.776B
1.52%		11.912B
10.54%		11.922B
0.08%		12.584B
5.55%		12.877B
2.33%		13.477B
4.66%		13.622B
1.08%		14.111B
3.59%		13.777B
-2.37%		13.572B
-1.49%
EBIT
YoY % growth
GSK ebit by date.GSK ebit by date.
8.321B
-0.88%		8.225B
-1.15%		9.598B
16.69%		10.024B
4.44%		10.752B
7.26%		11.122B
3.44%		12.859B
15.62%		12.158B
-5.45%		11.852B
-2.52%		10.999B
-7.20%		10.412B
-5.34%
Operating Margin
GSK operating margin by date.GSK operating margin by date.
27.44%26.21%29.38%28.76%29.60%29.75%33.09%31.52%30.51%29.63%28.36%
EPS
YoY % growth
GSK eps by date.GSK eps by date.
3.17
4.85%		3.26
2.77%		3.51
7.84%		3.80
8.20%		4.13
8.71%		4.26
3.14%		4.63
8.81%		4.48
-3.27%		4.36
-2.77%		4.05
-7.04%		3.84
-5.23%

All data in GBP

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		0.92
0.81%		0.98
3.32%		1.14
1.54%		0.67
28.49%		1.09
17.42%		1.16
18.34%		1.33
16.93%		0.69
3.11%
Revenue
Q2Q % growth		7.916B
5.32%		8.606B
7.76%		9.261B
8.35%		9.255B
7.39%		8.312B
5.00%		8.91B
3.53%		9.548B
3.10%		9.553B
3.22%
EBITDA
Q2Q % growth		2.91B
-7.24%		3.093B
-30.01%		3.386B
-38.51%		2.44B
-52.51%		N/AN/AN/AN/A
EBIT
Q2Q % growth		2.581B
11.54%		2.737B
12.31%		3.123B
12.06%		2.038B
18.08%		2.951B
14.34%		3.138B
14.65%		3.544B
13.48%		2.045B
0.34%

All data in GBP

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

GSK Yearly Revenue VS EstimatesGSK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
GSK Yearly EPS VS EstimatesGSK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
6.80%
EPS Next 5 Year
5.01%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
3.74%
Revenue Next 5 Year
2.87%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
11.62%
EBIT Next 5 Year
8.05%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

GSK PLC-SPON ADR / GSK Forecast FAQ

What do analysts expect the price target to be for GSK PLC-SPON ADR (GSK)?

32 analysts have analysed GSK and the average price target is 56.15 USD. This implies a price decrease of -3.55% is expected in the next year compared to the current price of 58.21.

When does GSK PLC-SPON ADR (GSK) report earnings?

GSK PLC-SPON ADR (GSK) will report earnings on 2026-04-29.

Can you provide the consensus estimates for GSK PLC-SPON ADR next earnings?

The consensus EPS estimate for the next earnings of GSK PLC-SPON ADR (GSK) is 0.92 USD and the consensus revenue estimate is 7.92B USD.

What is the number of analysts for GSK stock?

The number of analysts covering GSK PLC-SPON ADR (GSK) is 32.